Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study
- PMID: 39285685
- DOI: 10.1111/dom.15946
Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study
Abstract
Aims: To explore the associations between cuprotosis-related genes (CRGs) across different stages of liver disease in metabolic dysfunction-associated fatty liver disease (MAFLD), including hepatocellular carcinoma (HCC).
Materials and methods: We analysed several bulk RNA sequencing datasets from patients with MAFLD (n = 331) and MAFLD-related HCC (n = 271) and two MAFLD single-cell RNA sequencing datasets. To investigate the associations between CRGs and MAFLD, we performed differential correlation, logistic regression and functional enrichment analyses. We also validated the findings in an independent Wenzhou PERSONS cohort of MAFLD patients (n = 656) used for a genome-wide association study (GWAS).
Results: GLS, GCSH and ATP7B genes showed significant differences across the MAFLD spectrum and were significantly associated with liver fibrosis stages. GLS was closely associated with fibrosis stages in patients with MAFLD and those with MAFLD-related HCC. GLS is predominantly expressed in monocytes and T cells in MAFLD. During the progression of metabolic dysfunction-associated fatty liver to metabolic-associated steatohepatitis, GLS expression in T cells decreased. GWAS revealed that multiple single nucleotide polymorphisms in GLS were associated with clinical indicators of MAFLD.
Conclusions: GLS may contribute to liver inflammation and fibrosis in MAFLD mainly through cuprotosis and T-cell activation, promoting the progression of MAFLD to HCC. These findings suggest that cuprotosis may play a role in MAFLD progression, potentially providing new insights into MAFLD pathogenesis.
Keywords: bulk RNA‐seq; cuprotosis; genome‐wide association study; hepatocellular carcinoma; metabolic dysfunction‐associated fatty liver disease; sing‐cell RNA‐seq.
© 2024 John Wiley & Sons Ltd.
References
REFERENCES
-
- Huang DQ, El‐Serag HB, Loomba R. Global epidemiology of NAFLD‐related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223‐238.
-
- Eslam M, El‐Serag HB, Francque S, et al. Metabolic (dysfunction)‐associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19:638‐651.
-
- Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542‐1556.
-
- Wang TY, George J, Zheng MH. Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. Hepatobiliary Surg Nutr. 2021;10:849‐852.
-
- Rios RS, Zheng KI, Zheng MH. Non‐alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J. 2021;134:2911‐2921.
Publication types
MeSH terms
Associated data
- Actions
- Actions
Grants and funding
- 82070588/The National Natural Science Foundation of China
- 82370577/The National Natural Science Foundation of China
- A Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney
- APP2001692/Project, Ideas and Investigator grants
- APP1107178/Project, Ideas and Investigator grants
- APP1108422/Project, Ideas and Investigator grants
- APP1196492/Project, Ideas and Investigator grants
- APP1053206/A National Health and Medical Research Council of Australia (NHMRC) Program Grant
- NIHR203319/Part by the Southampton NIHR Biomedical Research Centre
- Grants from the School of Medicine, University of Verona, Verona, Italy
- 2021/ATRG2028/A Cancer Institute, NSW Grant
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous